Skip to content
Review Open access

More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

Sep 2026 · Alzheimer's & Dementia · Vol 22 · 1 citation · 29 references
Medicine

Abstract

Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.

Read PDF

Similar papers

Aug 2026

Amyloid-Targeting Treatments in Patients With Non-Alzheimer Disease Copathologies.

This Viewpoint examines how clinicians should approach amyloid-targeting therapies in patients with Alzheimer disease and suspected copathologies, emphasizing individualized decision-making, current evidence gaps, and the need for prospective studies.

Andy J. Liu, Suzanne E. Schindler, Heather E. Whitson · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.